Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8N428

UPID:
GLT16_HUMAN

ALTERNATIVE NAMES:
Polypeptide GalNAc transferase 16; Polypeptide GalNAc transferase-like protein 1; Polypeptide N-acetylgalactosaminyltransferase-like protein 1; Protein-UDP acetylgalactosaminyltransferase-like protein 1; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase-like protein 1

ALTERNATIVE UPACC:
Q8N428; Q4KMG3; Q58A55; Q9ULT9

BACKGROUND:
The enzyme Polypeptide N-acetylgalactosaminyltransferase 16, with its alternative identities including Polypeptide GalNAc transferase-like protein 1 and Protein-UDP acetygalactosaminyltransferase-like protein 1, is integral to the initial stages of O-linked oligosaccharide biosynthesis. This process involves the enzyme-mediated transfer of N-acetyl-D-galactosamine to serine or threonine on the target protein, marking a critical step in cellular glycosylation pathways.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Polypeptide N-acetylgalactosaminyltransferase 16 holds the promise of unveiling novel therapeutic avenues.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.